A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

Ischemic stroke has a high recurrence rate despite treatment. This underlines the
significance of investigating new possible cerebrovascular risk factors, such as the acquired …

Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and
enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic …

Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), polycythemia
vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell …

Abstract The recently published International Consensus Classification (ICC) of myeloid
neoplasms summarized the results of an in-depth effort by pathologists, oncologists, and …

Thrombosis is a major cause of morbidity and mortality in polycythemia vera (PV) and
essential thrombocythemia (ET). The pathophysiology of thrombosis in these disorders …

DOACs emerged as a treatment of choice for secondary prevention of VTE and thrombosis
prophylaxis in AF in the general population, and may be an attractive alternative to VKAs in …

Objective: The risk of thrombosis in myeloproliferative neoplasms, such as primary
myelofibrosis varies depending on the type of key driving mutation (JAK2 [janus kinase 2] …

Background Neutrophils participate in the pathogenesis of thrombosis through the formation
of neutrophil extracellular traps (NETs). Thrombosis is the main cause of morbidity and …